| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia
|
Giles, Francis J
|
|
2004
|
28 |
4 |
p. 353-357
5 p.
|
artikel
|
| 2 |
Allelotyping of gastrointestinal nasal-type NK/T-cell lymphoma
|
Wan, Maxim
|
|
2004
|
28 |
4 |
p. 339-343
5 p.
|
artikel
|
| 3 |
Angiogenesis in acute and chronic lymphocytic leukemia
|
Molica, Stefano
|
|
2004
|
28 |
4 |
p. 321-324
4 p.
|
artikel
|
| 4 |
C-kit receptor expression in acute leukemias—association with patient and disease characteristics and with outcome
|
Tsao, Anne S
|
|
2004
|
28 |
4 |
p. 373-378
6 p.
|
artikel
|
| 5 |
Combination of all-trans retinoic acid and lithium chloride surmounts a retinoid differentiation block induced by expression of Scl and Rbtn2 transcription factors in myeloid leukemia cells
|
Rice, Anna M
|
|
2004
|
28 |
4 |
p. 399-403
5 p.
|
artikel
|
| 6 |
Comparison of M-FISH and conventional cytogenetic analysis in accelerated and acute phases of CML
|
Brizard, Françoise
|
|
2004
|
28 |
4 |
p. 345-348
4 p.
|
artikel
|
| 7 |
Corrigendum to “Novel regimen for the treatment of juvenile myelomonocytic leukemia (JMML)” [Leuk. Res. 28 (2004) 167–170]
|
Kang, Hyoung Jin
|
|
2004
|
28 |
4 |
p. 427-
1 p.
|
artikel
|
| 8 |
Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase
|
Moravcová, Jana
|
|
2004
|
28 |
4 |
p. 415-419
5 p.
|
artikel
|
| 9 |
Distinct cellular origins of primary effusion lymphoma with and without EBV infection
|
Hamoudi, Rifat
|
|
2004
|
28 |
4 |
p. 333-338
6 p.
|
artikel
|
| 10 |
Domains involved in ETO and human N-CoR interaction and ETO transcription repression
|
Wang, Jianxiang
|
|
2004
|
28 |
4 |
p. 409-414
6 p.
|
artikel
|
| 11 |
Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients
|
Galimberti, Sara
|
|
2004
|
28 |
4 |
p. 367-372
6 p.
|
artikel
|
| 12 |
Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines
|
van der Kuip, Heiko
|
|
2004
|
28 |
4 |
p. 405-408
4 p.
|
artikel
|
| 13 |
Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis
|
Musto, Pellegrino
|
|
2004
|
28 |
4 |
p. 421-422
2 p.
|
artikel
|
| 14 |
Letter to the Editor
|
Gao, Xiaoling
|
|
2004
|
28 |
4 |
p. 423-
1 p.
|
artikel
|
| 15 |
Methylation profiling in multiple myeloma
|
Chim, C.S
|
|
2004
|
28 |
4 |
p. 379-385
7 p.
|
artikel
|
| 16 |
Peroxisome proliferator-activated receptor γ ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia
|
Zang, Chuanbing
|
|
2004
|
28 |
4 |
p. 387-397
11 p.
|
artikel
|
| 17 |
Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies
|
Rubnitz, Jeffrey E
|
|
2004
|
28 |
4 |
p. 349-352
4 p.
|
artikel
|
| 18 |
Prognostic significance of Fas (CD95) and TRAIL receptors (DR4/DR5) expression in acute myelogenous leukemia
|
Min, Young Joo
|
|
2004
|
28 |
4 |
p. 359-365
7 p.
|
artikel
|
| 19 |
Reply to the Letter to the Editor
|
DeCoteau, John
|
|
2004
|
28 |
4 |
p. 425-426
2 p.
|
artikel
|
| 20 |
Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives
|
Musto, Pellegrino
|
|
2004
|
28 |
4 |
p. 325-332
8 p.
|
artikel
|
Tijdschrift beschrijving